AIM BREAKFAST – 6th September 2016
Set Menu AIM:
Total number of AIM Companies (Incl Susp): 1,005
Total number of AIM Companies trading: 990*
* As at 05 September 2016
Dish of the Day:
No Primary Today
No Primary Today
Off the Menu:
No AIM Leavers today
No AIM Leavers today
Set Menu ISDX Growth:
Total number of ISDX Growth Market Companies (Incl Susp): *
Total number of ISDX Growth Market Companies trading: *
* As at 05 September 2016
Dish of the Day:
Off the Menu:
What’s Cooking in the IPO Kitchen?
Misys— The press reports that the Banking Technology provider owned by Vista Equity Partners is seeking a £5.5bn float in London
Bacanora Lithium— To list on AIM around 28 Sep as holding company for TSX listed Bacanora Minerals at £100m market cap
Aura Energy—ASX listed uranium developer (ASX:AEE) expected to join AIM 8 September raising up to £2.85m at £8.1m mkt cap
Instem (INS.L) 259p £40.7m
The provider of IT solutions to the global early development healthcare market, yesterday afternoon announced the acquisition of Notocord® for up to €4.2m, net of any cash acquired. The Acquisition is expected to be immediately earnings enhancing. Notocord® provides software solutions for data acquisition & analysis & is a highly respected name in the life sciences software industry. FY16E forecasts are looking for £18.3m revenues & 10.37pEPS. Notocord® had sales of €2.25m and operating profits of €0.7m in 2015.
OptiBiotix Health* (OPTI.L) 74p £57.8m
The life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care has announced the results of an independent consumer survey of the GoFigure® products. containing the company’s patented SlimBiome®. Weight Management Formulation. 100% of customers reported a reduction in food intake, and weight loss for those who used the products over a continued period. 93% reported reduced snacking and 83% felt less hungry.
ReNeuron Group (RENE.L) 2.88p £90.8m
AGM Trading update from The developer of cell-based therapeutics. All patients have been treated in the PISCES II Phase II clinical trial of the CTX cell therapy candidate for patients with motor disability as a result of ischaemic stroke. Hopes to file a Phase II/III trial application in Q1 2017. The Phase I/II clinical trial of the human Retinal Progenitor cell therapy candidate for Retinitis Pigmentosa (RP) is also proceeding well and a Phase I trial is underway for critical limb ischaemia. Pre-clinical work continues on the exosome nanomedicine programme.
Mobile Streams (MOS.L) 4p £1.48m
Trading statement from the emerging markets focused mobile media company stating that in relation to its Indian Operations its local subsidiary, has exceeded the important milestone of reaching 50,000 active subscribers. MOS expects to add additional billing connectivity to the next three largest network operators in India before the end of the calendar year. This has the potential to increase the addressable audience from the current c.600 million mobile users to around 900 million such users.
Forbidden Technologies (FBT.L) 9.5p £14.3m
FY Jun 2016 Interims from cloud video platform owner. Revenues flat at £327k but invoiced sales up 25% to £445k. EBITDA loss of £1,041k broadly flat. Liquid funds of £1.8m following share issue. FBT has completed an organisational restructuring saving circa £1.0m in operating and capitalised costs on an annualised basis. ‘An increase in direct sales capacity has given us a stronger top-line focus, and I look forward to seeing our growth continue in the second half.’
1PM (OPM.L) 65.5p £34.4m
Final results from independent specialist provider of finance facilities to the SME sector for y/e May2016. Organic revenue at 1PM increased 45% to £8.0m. Group revenue of £12.5m including £4.5m from acquired companies. Group profit before tax and exceptional items increased to £3.7m (2015: £1.6m). Basic earnings per share up 58% to 5.87 pence. Dividend declared of 0.50 pence, up 43%. Deferred income of £14.3m. The new financial year has started well, being in line with management’s expectations.
Ebiquity (EBQ.L) 100p £77.2m
The independent marketing analytics specialist, has announced the global rollout of its new Ebiquity Portfolio platform which allows clients to view, sort and analyse competitor advertising creatives and spend, across 15 European countries and up to 80 territories worldwide. The new platform is being rolled out to more than 120 companies with users across every continent, who are able to access the Ebiquity’s database containing over 25million individual ads. The PE is 9.1x FY2016E EPS.
Draper Esprit (GROW.L) 302.5p £123m
The venture capital investor involved in the creation, funding and development of high-growth digital technology businesses in the UK, the Republic of Ireland and Europe, has accepted, along with other investors, a conditional offer for Dublin based portfolio company Movidius Ltd from Intel Corporation for an undisclosed sum. The sale is expected to complete before the end of 2016 and is estimated to increase the Group’s total NAV by approximately 21%, vs NAV reported at admission.
REDX Pharma (REDX.L) 25.5p £23.9m
The drug development company, has entered into an agreement with Quay Pharma to manufacture the clinical trial supplies for Redx’s Porcupine inhibitor (RXC004), which has the potential to tackle hard-to-treat cancers, such as pancreatic, triple negative breast and head and neck cancers. As previously reported, first-in-human studies for the Porcupine inhibitor are expected to commence in the first quarter of 2017.
C4X Discovery (C4XD.L) 101.00p £33.3m
The innovative drug discovery engine, today announces that it has raised £5.0 million (Cornerstoned by Calculas Capital who invested £3m) gross, at 102p a 4.2% discount to yesterday’s close. Proceeds will be used to: Progress the Group’s existing pre-clinical pipeline towards clinical development and a commercially attractive partnering point; Invest in developing new lead compounds against highly valuable drug targets including those identified by Taxonomy3® and provide sufficient working capital to fund the Group’s operations.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX. If you would like to unsubscribe, please email firstname.lastname@example.org with “unsubscribe me”.